Previous 10 | Next 10 |
MOUNTAIN VIEW, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter o...
2023-05-11 22:14:09 ET IRIDEX Corporation (IRIX) Q1 2023 Results Conference Call May 11, 2023 05:00 PM ET Company Participants Trip Taylor - Investor Relations, Gilmartin Group David Bruce - President and CEO Fuad Ahmad - Interim Chief Financial Officer Con...
2023-05-11 16:19:31 ET Iridex press release ( NASDAQ: IRIX ): Q1 GAAP EPS of -$0.13. Revenue of $13.7M (+2.2% Y/Y). Reiterates FY 2023 revenue guidance of $57 million to $59 million. For further details see: Iridex reports Q1 results, reaffirms FY 2023 revenu...
MOUNTAIN VIEW, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 1, 2023. First...
MOUNTAIN VIEW, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter o...
2023-03-29 08:32:58 ET The following slide deck was published by IRIDEX Corporation in conjunction with this event. For further details see: IRIDEX (IRIX) Investor Presentation - Slideshow
2023-03-09 22:12:04 ET IRIDEX Corporation (IRIX) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM Company Participants Philip Taylor - Investor Relations, Gilmartin Group David Bruce - President and CEO Fuad Ahmad - Interim Chief Financial Officer Con...
2023-03-09 16:15:19 ET IRIDEX press release ( NASDAQ: IRIX ): Q4 GAAP EPS of -$0.07 beats by $0.04 . Revenue of $15.2M (-0.3% Y/Y) beats by $0.04M . Retina product revenue decreased 11% year-over-year to $8.1 million Iridex projects Cyclo G6 probe sales of ...
MOUNTAIN VIEW, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and year ended December 31, 202...
MOUNTAIN VIEW, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming 35 th Annual Roth Conference i...
News, Short Squeeze, Breakout and More Instantly...
MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company...